ENDORISK clinical implementation study (ENDORISK-I)

ENDORISK clinical implementation study (ENDORISK-I) - ENDORISK-I

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON57807

Enrollment

735

Registered

2024-11-01

Start date

2025-10-23

Completion date

Unknown

Last updated

2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

endometrial carcinoma uterine cancer Uterine cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Diagnosed with early stage endometrial carcinoma - Eligible for primary surgical treatment

Exclusion criteria

Exclusion criteria: - Unable to give informed consent - No understanding of Dutch or English language

Design outcomes

Primary

Measure	Time frame
• The proportion of identified LNM in patients with lymph node staging (positive predictive value (PPV)) compared to standard care • Proportion of patients who decide to have lymph node status assessed in ENDORISK care compared to standard care • Preoperative information provision for patients and shared-decision making with the use of ENDORISK compared to standard care	—

Secondary

Measure	Time frame
• Patients* disease- specific-, overall survival, and health-related quality of life compared to standard care • Patients* and doctors* use of and experiences with the ENDORISK-model • Impact of ENDORISK on regional care costs	—

Countries

Netherlands

Contacts

Public ContactJMA Pijnenborg

Radboud Universitair Medisch Centrum

endorisk@radboudumc.nl0631015109

Outcome results